GSK (GSK) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2202904/gsk-gsk-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2202904
Dec 27, 2023 - In the most recent trading session, GSK (GSK) closed at $37.10, indicating a +0.24% shift from the previous trading day.
0
GSK looking to boost pipeline with respiratory, auto-immune deals - report
https://seekingalpha.com/news/4050326-gsk-looking-to-boost-pipeline-with-respiratory-auto-immune-deals-report?source=feed_sector_healthcare
Dec 26, 2023 - GSK plans to strengthen its drug portfolio through acquisitions in respiratory and auto-immune areas, with a focus on deals worth around $2 billion over the...
0
Week In Review: Two Billion-Dollar Deals As 2023 Nears End - Hansoh-GSK; Nona-Pfizer
https://seekingalpha.com/article/4659466-week-in-review-two-billion-dollar-deals-2023-nears-end-hansoh-gsk-nona-pfizer?source=feed_all_articles
Dec 24, 2023 - GSK acquired ex-Greater China rights to a second ADC from Hansoh Pharma in a $1.7 billion agreement. Boston's Nona Biosciences out-licensed global rights for its MSLN-targeted ADC to Pfizer.
0
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
https://www.zacks.com/stock/news/2201105/gsk-hansoh-ink-deal-to-develop-lung-cancer-adc-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201105
Dec 21, 2023 - GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
0
GSK (GSK) Stock Moves -0.85%: What You Should Know
https://www.zacks.com/stock/news/2200785/gsk-gsk-stock-moves-0-85-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2200785
Dec 20, 2023 - The latest trading day saw GSK (GSK) settling at $36.19, representing a -0.85% change from its previous close.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
EU regulators recommend against renewing approval for GSK's Blenrep
https://seekingalpha.com/news/4046976-eu-regulators-recommend-against-renewing-approval-for-gsks-blenrep?source=feed_sector_healthcare
Dec 15, 2023 - EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (GSK) blood cancer drug Blenrep. According to Reuters, a European Me
0
GSK (GSK) Beats Stock Market Upswing: What Investors Need to Know
https://www.zacks.com/stock/news/2198311/gsk-gsk-beats-stock-market-upswing-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2198311
Dec 14, 2023 - GSK (GSK) concluded the recent trading session at $36.98, signifying a +0.65% move from its prior day's close.
0
GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use
https://www.zacks.com/stock/news/2196699/gsk-s-jemperli-gets-eu-nod-for-endometrial-cancer-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196699
Dec 12, 2023 - GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
0